ONE Holdings Subsidiary Files Invention Patent for Sarcandra Glabra Extraction
14 Outubro 2009 - 9:50AM
Marketwired
ONE Holdings, Corp. (OTCBB: ONEZ), a green process manufacturer of
high-quality health supplements, organic fertilizers and
pesticides, announces that its subsidiary Green Planet
Bioengineering CO., LTD. (OTCBB: GPLB) has filed an invention
patent for Sarcandra Glabra.
The patent specifically covers the process and application of
extracting Isofraxidin and Flavonoid compounds synchronously from
Sarcandra Glabra. The new process will dramatically increase the
extraction rate from Sarcandra Glabra, and also significantly
improve the medicinal yield in the process. This will accelerate
the company's time to market its over-the-counter products. Up
until now, Sarcandra Glabra extraction was limited to a single
composition. The company expects to achieve commercial production
by the fourth quarter of this year.
"This is a very exciting technical development because of the
direct economic benefit ONE will reap from the process. It
dramatically increases our time to market in the high margin
over-the-counter business. We will be launching OTC products in Q4
of this year and look to see significant increase in our net
profits as a result," stated Mr. Min Zhao, President of ONE's China
operations.
"This is another great step forward for ONE. Increasing
profitability and product expansion is our key focus and this new
process will achieve both dramatically by enabling us to more
effectively enter the over-the-counter market next year," stated
ONE's CEO Marius Silvasan.
For a full list of Green Planet's products please visit the
Company's website: http://www.greenplanetbio.com/
About ONE Holdings, Corp.
ONE Holdings, Corp. ("ONE") (OTCBB: ONEZ) (www.onehcorp.com),
headquartered in Miami, FL, is a company utilizing green processes
specialized in raw chemicals and herbal extracts, natural
supplements and organic products. ONE is focused on the Asia
Pacific region. Key products include widely recognized Solanesol,
CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic
bamboo health food and beverages. ONE's growth plan targets an
aggressive acquisition driven strategy supported by strong organic
growth. Through ONE, small private companies gain access to
capital, experienced management and strategic insight. ONE builds
strong synergies amongst all subsidiaries to enhance shareholder
value. ONE is working with each subsidiary to promote organic and
acquisition driven growth.
About Green Planet
Green Planet Bioengineering CO., LTD. ("Green Planet")
(http://www.greenplanetbio.com) (OTCBB: GPLB), a subsidiary of ONE
Holdings, Corp. (OTCBB: ONEZ), is a high-tech bioengineering
enterprise that engages in research & development, production
and sale of various extracts from tobacco leaves residue destined
for health supplements and organic agricultural products. Green
Planet is headquartered in Miami, FL with its main operation
located in Sanming and Fuzhou, China. Since founded in 2005, Green
Planet offers a full range of high quality bio-ecological products
which include raw chemical materials such as CoQ10 and Solanesol,
organic fertilizers and pesticides and organic health nutrients and
supplements. The Company's unique position in the bioengineering
industry comes from its R&D using patented cutting-edge methods
to create abundant downstream products ranging from plant
indigenous medicine, pharmaceutical intermediates to a long list of
eco-friendly products.
This press release includes statements that constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"). Green
Planet Bioengineering, Co., Ltd. claims the protection of the
safe-harbor for forward-looking statements contained in the Reform
Act. These forward-looking statements are often characterized by
the terms "may," "believes," "projects," "expects," or
"anticipates," and do not reflect historical facts. Specific
forward-looking statements contained in this press release include,
but are not limited to: our successful integration of diversified
growth companies, impact of the company's expansion plan, and new
business development success, future financial results, development
and acquisition of new product lines and services, the impact of
competitive products or pricing from technological changes, the
effect of economic conditions and other uncertainties. The
forward-looking statements contained herein involve risks and
uncertainties that could cause actual results to differ materially
from the expectations contained in any such forward-looking
statements. These risks include, but are not limited to: failure to
manage operating expenses or integrate new companies and/or
technologies, each of which could have a material impact on our
business, our financial results, and the company's stock price.
These risks and other factors are detailed in the Company's regular
filings with the U.S. Securities and Exchange Commission. Most of
these factors are difficult to predict accurately and are generally
beyond the Company's control. Forward-looking statements speak only
as to the date they are made and Green Planet Bioengineering, Co.,
Ltd. does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the
forward-looking statements are made.
Company Contact: Jeanne Chan Senior VP Tel. +877.544.2288
jchan@onehcorp.com
Green Planet Bioengineer... (PK) (USOTC:GPLB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Green Planet Bioengineer... (PK) (USOTC:GPLB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024